8cyh
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics== | |
| - | + | <StructureSection load='8cyh' size='340' side='right'caption='[[8cyh]], [[Resolution|resolution]] 3.38Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[8cyh]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8CYH OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8CYH FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8cyh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8cyh OCA], [https://pdbe.org/8cyh PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8cyh RCSB], [https://www.ebi.ac.uk/pdbsum/8cyh PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8cyh ProSAT]</span></td></tr> |
| - | [[Category: | + | </table> |
| - | [[Category: | + | == Disease == |
| - | [[Category: | + | [https://www.uniprot.org/uniprot/MSLN_HUMAN MSLN_HUMAN] Antibodies against MSLN are detected in patients with mesothelioma and ovarian cancer. |
| - | [[Category: | + | == Function == |
| - | [[Category: | + | [https://www.uniprot.org/uniprot/MSLN_HUMAN MSLN_HUMAN] Membrane-anchored forms may play a role in cellular adhesion.<ref>PMID:8288629</ref> <ref>PMID:14676194</ref> Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.<ref>PMID:8288629</ref> <ref>PMID:14676194</ref> |
| - | [[Category: | + | == References == |
| - | [[Category: | + | <references/> |
| - | [[Category: | + | __TOC__ |
| - | [[Category: | + | </StructureSection> |
| - | [[Category: | + | [[Category: Homo sapiens]] |
| - | [[Category: | + | [[Category: Large Structures]] |
| - | [[Category: | + | [[Category: Bandaranayake AD]] |
| - | [[Category: | + | [[Category: Carter J]] |
| - | [[Category: | + | [[Category: Chan MK]] |
| + | [[Category: Clarke M]] | ||
| + | [[Category: Correnti CE]] | ||
| + | [[Category: Friend DJ]] | ||
| + | [[Category: Lin I]] | ||
| + | [[Category: Mehlin C]] | ||
| + | [[Category: Meshinchi S]] | ||
| + | [[Category: Olson JM]] | ||
| + | [[Category: Pilat K]] | ||
| + | [[Category: Ruff RO]] | ||
| + | [[Category: Rupert PB]] | ||
| + | [[Category: Strong RK]] | ||
Revision as of 05:39, 7 June 2023
Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics
| |||||||||||
Categories: Homo sapiens | Large Structures | Bandaranayake AD | Carter J | Chan MK | Clarke M | Correnti CE | Friend DJ | Lin I | Mehlin C | Meshinchi S | Olson JM | Pilat K | Ruff RO | Rupert PB | Strong RK
